Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Natera, Inc.
NTRA
$320.90
Name : Natera, Inc.
Sector : Healthcare
Industry: Diagnostics & Research
Mark. Cap: $46,531,346,432.00
EPSttm : -1.12
finviz dynamic chart for NTRA
Natera, Inc.
$320.90
2.86%
$8.92
NTRA — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

4.31

Margin Of Safety %

-8

Put/Call OI Ratio

0.83

EPS Next Q Diff

0.15

EPS Last/This Y

-0.13

EPS This/Next Y

1.39

Price

311.8

Target Price

412.75

Analyst Recom

1.44

Performance Q

-1.26

Upside

-112.9%

Beta

1.54

Ticker: NTRA




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-12NTRA397.880.991.3843955
2026-10-13NTRA395.741.001.1944003
2026-10-14NTRA394.891.012.5344910
2026-10-15NTRA404.661.020.2045305
2026-10-16NTRA393.371.000.7845647
2026-10-19NTRA399.70.862.1235594
2026-10-20NTRA405.70.870.4535899
2026-10-21NTRA414.280.870.6236099
2026-10-22NTRA401.830.860.2436349
2026-10-23NTRA403.950.820.7637685
2026-10-26NTRA404.730.821.6738058
2026-10-27NTRA412.160.830.3438211
2026-10-28NTRA424.260.800.5138973
2026-10-29NTRA436.130.790.5140094
2026-10-30NTRA414.130.792.5040316
2026-11-02NTRA378.740.801.9640618
2026-11-03NTRA387.080.811.7641127
2026-11-04NTRA390.760.823.6341364
2026-11-05NTRA363.660.822.3341674
2026-11-06NTRA313.30.841.4544311
2026-11-09NTRA320.020.840.4444761
2026-11-10NTRA311.960.830.9944903
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-12NTRA397.7458.5- -1.44
2026-10-13NTRA395.8458.5- -1.44
2026-10-14NTRA394.9658.5- -1.44
2026-10-15NTRA404.7058.5- -1.44
2026-10-16NTRA393.3856.2- -1.47
2026-10-19NTRA399.4156.2- -1.47
2026-10-20NTRA399.4156.2- -1.47
2026-10-21NTRA405.7556.2- -1.47
2026-10-22NTRA401.8656.2- -1.47
2026-10-23NTRA403.9556.2- -1.47
2026-10-26NTRA404.8456.2- -1.46
2026-10-27NTRA410.8356.2- -1.46
2026-10-28NTRA424.3656.2- -1.46
2026-10-29NTRA436.0956.2- -1.46
2026-10-30NTRA414.1056.2- -1.46
2026-11-02NTRA378.9556.2- -1.46
2026-11-03NTRA388.4856.2- -1.46
2026-11-04NTRA390.8856.2- -1.46
2026-11-05NTRA364.4056.2- -1.46
2026-11-06NTRA310.7856.2- -1.46
2026-11-09NTRA320.1556.2- -1.46
2026-11-10NTRA311.80-100.0- -1.65
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-12NTRA-6.211.384.71
2026-10-13NTRA-6.211.384.71
2026-10-14NTRA-6.211.384.71
2026-10-15NTRA-6.211.384.71
2026-10-16NTRA-6.211.384.71
2026-10-19NTRA-6.701.354.71
2026-10-20NTRA-6.701.354.71
2026-10-21NTRA-6.711.354.71
2026-10-22NTRA-6.691.354.71
2026-10-23NTRA-6.691.354.71
2026-10-26NTRA-6.721.094.71
2026-10-27NTRA-6.721.094.34
2026-10-28NTRA-6.721.094.34
2026-10-29NTRA-6.721.094.34
2026-10-30NTRA-6.681.094.34
2026-11-02NTRA-6.710.974.34
2026-11-03NTRA-6.710.974.34
2026-11-05NTRA-6.800.974.34
2026-11-06NTRA-6.740.974.34
2026-11-09NTRA-6.640.664.31
2026-11-10NTRA-6.640.664.31
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

-0.39

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.24

Insider Transactions

-6.64

Institutional Transactions

0.66

Beta

1.54

Average Sales Estimate Current Quarter

771

Average Sales Estimate Next Quarter

833

Fair Value

285.57

Quality Score

50

Growth Score

58

Sentiment Score

59

Actual DrawDown %

28.7

Max Drawdown 5-Year %

-75.7

Target Price

412.75

P/E

Forward P/E

PEG

P/S

15.55

P/B

24.09

P/Free Cash Flow

862.18

EPS

-1.15

Average EPS Est. Cur. Y​

-1.65

EPS Next Y. (Est.)

-0.26

Target Price Estimates Raised

Target Price Estimates Lowered

3

Profit Margin

-5.66

Relative Volume

1.02

Return on Equity vs Sector %

-35.1

Return on Equity vs Industry %

-20.5

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.22

EBIT Estimation

◆ NTRA Healthcare
$311.98
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
18/20
Pullback
21/25
Volume
1/15
Valuation
12/20
TP/AR
6/10
Options
3/10
RSI
30.7
Range 1M
6.7%
Sup Dist
0.4%
🚀
Momentum Growth
Ride accelerating trends
N/A
51 /100
WEAK
Momentum
16/25
Growth
17/30
Estimates
9/20
Inst/Vol
5/15
Options
4/10
EPS Yr
-3.5%
EPS NY
69.7%
52W%
51.4%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟡 HOLD +7.8% upside
Quality
6/30
Valuation
4/30
Growth
13/25
Stability
9/10
LT Trend
1/5
Upside
+7.8%
Quality
50
MoS
-8%
NTRA — P/E HistoricalDiagnostics & Research
Natera, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 6135
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
NTRA

Latest News

—
Caricamento notizie per NTRA…
stock quote shares NTRA – Natera, Inc. Stock Price stock today
news today NTRA – Natera, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NTRA – Natera, Inc. yahoo finance google finance
stock history NTRA – Natera, Inc. invest stock market
stock prices NTRA premarket after hours
ticker NTRA fair value insiders trading